Skip to main content

Advertisement

SpringerLink
Log in

Immunmodulation als innovative Therapie bei Kopf-Hals-Tumoren

Aktuelle Entwicklungen

Immunomodulation as innovative therapy for head and neck tumors

Current developments

  • Leitthema
  • Published:
HNO Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Zusammenfassung

Das Plattenepithelkarzinom des Kopf-Hals-Bereichs (PKH) ist durch seine starke Immunsuppression und ausgeprägte Immune-escape-Mechanismen gekennzeichnet. Die immuntherapeutischen Ansätze gewinnen weiter an Bedeutung, wobei sich die Studienlandschaft deutlich in Richtung antikörperbasierter Immuncheckpointmodulation verschoben hat. Der Einsatz der Immuntherapie als kurativer Ansatz oder als Rezidivprophylaxe ist anzustreben.

Abstract

Head and neck squamous cell carcinoma (HNSCC) is characterized by its intense immune suppression and its elaborate immune escape mechanisms. Due to the fact that survival rates remain low, the role of immunotherapy has become more important and the focus of current clinical studies has shifted toward antibody-based immune checkpoint modulation. Application of immunotherapy in curative settings or for prevention of recurrent disease would be desirable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Alexandrov LB, Nik-Zainal S, Wedge DC et al (2013) Signatures of mutational processes in human cancer. Nature 500:415–421

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Antonia SJ (2015) Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T‑lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. J Clin Oncol 33(15 suppl):3014

    Google Scholar 

  3. Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‑year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28

    Article  CAS  PubMed  Google Scholar 

  4. Croft M, Benedict CA, Ware CF (2013) Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov 12:147–168

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Dietz A, Loeffler M, Rosolowski M et al (2015) Gene expression analyses and their possible clinical benefit in head and neck cancer. HNO (Epub ahead of print)

  6. Fayette J (2014) Randomized phase II study of MEHD7945A (MEHD) vs cetuximab (cet) in >= 2nd-line recurrent/metastatic squamous cell carcinoma of the head & neck (RMSCCHN) progressive on/after platinum-based chemotherapy (PTCT). Ann Oncol 25(4):iv340–iv356. doi:10.1093/annonc/mdu340.1

    Google Scholar 

  7. Fishman MN, Thompson JA, Pennock GK et al (2011) Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res 17:7765–7775

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Freeman SM, Franco JL, Kenady DE et al (2011) A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck. Am J Clin Oncol 34:173–178

    CAS  PubMed  Google Scholar 

  9. Hoffmann TK, Muller-Berghaus J, Ferris RL et al (2002) Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res 8:1787–1793

    PubMed  Google Scholar 

  10. Hoffmann TK, Schuler PJ (2013) Antigen-specific immunotherapy in head and neck cancer. Advances in Cellular and Molecular. Otolaryngology 1:21758–21766

    Google Scholar 

  11. Hoffmann TK, Sonkoly E, Hauser U et al (2008) Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma. Oral Oncol 44:1100–1109

    Article  CAS  PubMed  Google Scholar 

  12. Jimeno A (2014) Phase 2 study of dalantercept in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 32(5 suppl):6045

    Google Scholar 

  13. Karcher J, Dyckhoff G, Beckhove P et al (2004) Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res 64:8057–8061

    Article  CAS  PubMed  Google Scholar 

  14. Laban S, Doescher J, Schuler PJ et al (2015) Immunotherapy of head and neck tumors : Highlights of the ASCO Meeting 2015. HNO 63:612–619

    Article  CAS  PubMed  Google Scholar 

  15. Lui VW, Peyser ND, Ng PK et al (2014) Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc Natl Acad Sci U S A 111:1114–1119

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Makker V, Filiaci VL, Chen LM et al (2015) Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N. Gynecol Oncol 138:24–29

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Malhotra A, Sendilnathan A, Old MO et al (2015) Oncolytic virotherapy for head and neck cancer: current research and future developments. Oncolytic Virotherapy 2015:83–93

    Google Scholar 

  18. Postow MA (2015) Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 35:76–83

    Article  Google Scholar 

  19. Reynolds KL (2014) A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer. J Clin Oncol 32(5 suppl):2517

    Google Scholar 

  20. Rosenberg SA, Yang JC, Sherry RM et al (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T‑cell transfer immunotherapy. Clin Cancer Res 17:4550–4557

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Ruzsa A, Sen M, Evans M et al (2014) Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naive patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Invest New Drugs 32:1278–1284

    Article  CAS  PubMed  Google Scholar 

  22. Schuler PJ, Harasymczuk M, Visus C et al (2014) Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res 20:2433–2444

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Schuler PJ, Hoffmann TK, Gauler TC et al (2013) Immunotherapy of head and neck cancer. Current developments. HNO 61:559–572

    Article  CAS  PubMed  Google Scholar 

  24. Schuler PJ, Schilling B, Harasymczuk M et al (2012) Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T‑cell subsets in cancer patients. Eur J Immunol 42:1876–1885

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Seiwert TY (2015) Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. J Clin Oncol 33(suppl):LBA6008

    Google Scholar 

  26. Seiwert TY, Fayette J, Cupissol D et al (2014) A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol 25:1813–1820

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Smith C, Tsang J, Beagley L et al (2012) Effective treatment of metastatic forms of Epstein-Barr virus-associated Nasopharyngeal carcinoma with a novel Adenovirus-based adoptive immunotherapy. Cancer Res 72(5):1116–1125

    Article  CAS  PubMed  Google Scholar 

  28. Taylor GS, Jia H, Harrington K et al (2014) A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin Cancer Res 20:5009–5022

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Thierauf J, Veit JA, Affolter A et al (2015) Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck. Melanoma Res 25:503–509

    Article  CAS  PubMed  Google Scholar 

  30. Timar J, Forster-Horvath C, Lukits J et al (2003) The effect of leukocyte interleukin injection (Multikine) treatment on the peritumoral and intratumoral subpopulation of mononuclear cells and on tumor epithelia: a possible new approach to augmenting sensitivity to radiation therapy and chemotherapy in oral cancer-a multicenter phase I/II clinical Trial. Laryngoscope 113:2206–2217

    Article  CAS  PubMed  Google Scholar 

  31. Uyttenhove C, Pilotte L, Theate I et al (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:1269–1274

    Article  CAS  PubMed  Google Scholar 

  32. Van Der SSJ, Davies DM, Wilkie S et al (2013) Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity? J Immunol 191:4589–4598

    Article  Google Scholar 

  33. Vermorken JB, Stohlmacher-Williams J, Davidenko I et al (2013) Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 14:697–710

    Article  CAS  PubMed  Google Scholar 

  34. Vogelstein B, Papadopoulos N, Velculescu VE et al (2013) Cancer genome landscapes. Science 339:1546–1558

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122–133

    Article  CAS  PubMed  Google Scholar 

  36. Yoshitake Y, Fukuma D, Yuno A et al (2015) Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin Cancer Res 21:312–321

    Article  CAS  PubMed  Google Scholar 

  37. Zandberg DP, Rollins S, Goloubeva O et al (2015) A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). Cancer Immunol Immunother 64:367–379

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsklinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie, Universitätsklinikum Ulm, Frauensteige 12, 89075, Ulm, Deutschland

    P. J. Schuler, J. C. Doescher, S. Laban & T. K. Hoffmann

Authors
  1. P. J. Schuler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. C. Doescher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Laban
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. K. Hoffmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. J. Schuler.

Ethics declarations

Interessenkonflikt

P.J. Schuler, J.C. Doescher, S. Laban und T.K. Hoffmann geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schuler, P.J., Doescher, J.C., Laban, S. et al. Immunmodulation als innovative Therapie bei Kopf-Hals-Tumoren. HNO 64, 470–478 (2016). https://doi.org/10.1007/s00106-016-0131-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00106-016-0131-0

Schlüsselwörter

Keywords

Search

Navigation